AAAAAA

   
Results: 1-11 |
Results: 11
GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-INFECTED ADULTS AND ADOLESCENTS
Authors: ANDERSON J ARMSTEAD R BAKER AC BARR D BOZZETTE S COX S DELANEY M GORDIN F GREAVES W HARRINGTON M HENNING JJ HIRSCH MS JACOBS J MARLINK R MAXWELL C MELLORS JW NASH DB PERRYMAN S SCHOOLEY RT SHERER R SPECTOR SA TORRES G VOLBERDING P BRADY BA COHEN O DANIELS EM FEIGAL D FEINBERG M GAYLE HD GRAYDON TR KAPLAN J MACHER A MARTIN RF MASUR H MOFENSON L MURRAY J ONEILL J PEREZ LC RISEBERG R SHEKAR S STANLEY SK WHITESCARVER J CARPENTER C BALLY G RACHLIS A STANLEY SK BRADY BA DANIELS EM
Citation: J. Anderson et al., GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-INFECTED ADULTS AND ADOLESCENTS, Annals of internal medicine, 128(12), 1998, pp. 1079-1100
COUNSELING PATIENTS ABOUT HIV RISK FROM ORAL SEX
Authors: GERBERT B HERZIG K VOLBERDING P
Citation: B. Gerbert et al., COUNSELING PATIENTS ABOUT HIV RISK FROM ORAL SEX, Journal of general internal medicine, 12(11), 1997, pp. 698-704
PHASE-1 STUDY OF COMBINATION THERAPY WITH L-697,661 AND ZIDOVUDINE
Authors: SCHOOLEY RT CAMPBELL TB KURITZKES DR BLASCHKE T STEIN DS ROSANDICH ME PHAIR J POTTAGE JC MESSARI F COLLIER A KAHN J RAY G CURTIS S BAKHTIARI M KESSLER H COOMBS R COREY L VOLBERDING P CALANDRA G MASSARI F
Citation: Rt. Schooley et al., PHASE-1 STUDY OF COMBINATION THERAPY WITH L-697,661 AND ZIDOVUDINE, Journal of acquired immune deficiency syndromes and human retrovirology, 12(4), 1996, pp. 363-370
ZIDOVUDINE SIDE-EFFECTS AS REPORTED BY BLACK, HISPANIC, AND WHITE NON-HISPANIC PATIENTS WITH EARLY HIV DISEASE - COMBINED ANALYSIS OF 2 MULTICENTER PLACEBO-CONTROLLED TRIALS
Authors: JACOBSON MA GUNDACKER H HUGHES M FISCHL M VOLBERDING P
Citation: Ma. Jacobson et al., ZIDOVUDINE SIDE-EFFECTS AS REPORTED BY BLACK, HISPANIC, AND WHITE NON-HISPANIC PATIENTS WITH EARLY HIV DISEASE - COMBINED ANALYSIS OF 2 MULTICENTER PLACEBO-CONTROLLED TRIALS, Journal of acquired immune deficiency syndromes and human retrovirology, 11(1), 1996, pp. 45-52
THE PREDICTIVE VALUE OF CHANGES IN SEROLOGIC AND CELL MARKERS OF HIV ACTIVITY FOR SUBSEQUENT CLINICAL OUTCOME IN PATIENTS WITH ASYMPTOMATICHIV DISEASE TREATED WITH ZIDOVUDINE
Authors: JACOBSON MA DEGRUTTOLA V REDDY M ARDUINO JM STRICKLAND S REICHMAN RC BARTLETT JA PHAIR JP HIRSCH MS COLLIER AC SOEIRO R VOLBERDING P
Citation: Ma. Jacobson et al., THE PREDICTIVE VALUE OF CHANGES IN SEROLOGIC AND CELL MARKERS OF HIV ACTIVITY FOR SUBSEQUENT CLINICAL OUTCOME IN PATIENTS WITH ASYMPTOMATICHIV DISEASE TREATED WITH ZIDOVUDINE, AIDS, 9(7), 1995, pp. 727-734
TREATMENT TRENDS IN HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE - SAN-FRANCISCO, CALIFORNIA 16 JULY 1993 - INTRODUCTION
Authors: VOLBERDING P
Citation: P. Volberding, TREATMENT TRENDS IN HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE - SAN-FRANCISCO, CALIFORNIA 16 JULY 1993 - INTRODUCTION, The Journal of infectious diseases, 171, 1995, pp. 79-80
THE NEED FOR ADDITIONAL OPTIONS IN THE TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
Authors: VOLBERDING P
Citation: P. Volberding, THE NEED FOR ADDITIONAL OPTIONS IN THE TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION, The Journal of infectious diseases, 171, 1995, pp. 150-154
PREVALENCE AND PATTERNS OF USE OF CONCOMITANT MEDICATIONS AMONG PARTICIPANTS IN 3 MULTICENTER HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-I CLINICAL-TRIALS
Authors: FOGELMAN I LIM L BASSETT R VOLBERDING P FISCHL MA STANLEY K COTTON DJ
Citation: I. Fogelman et al., PREVALENCE AND PATTERNS OF USE OF CONCOMITANT MEDICATIONS AMONG PARTICIPANTS IN 3 MULTICENTER HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-I CLINICAL-TRIALS, Journal of acquired immune deficiency syndromes, 7(10), 1994, pp. 1057-1063
EDUCATING PRIMARY-CARE PROVIDERS ABOUT HIV DISEASE - MULTIDISCIPLINARY INTERACTIVE MECHANISMS
Authors: MACHER A GOOSBY E BARKER L VOLBERDING P GOLDSCHMIDT R BALANO KB WILLIAMS A HOENIG L GOULD B DANIELS E
Citation: A. Macher et al., EDUCATING PRIMARY-CARE PROVIDERS ABOUT HIV DISEASE - MULTIDISCIPLINARY INTERACTIVE MECHANISMS, Public health reports, 109(3), 1994, pp. 305-310
SERUM P24 ANTIGEN LEVEL AS AN INTERMEDIATE END-POINT IN CLINICAL-TRIALS OF ZIDOVUDINE IN PEOPLE INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
Authors: DEGRUTTOLA V BECKETT LA COOMBS RW ARDUINO JM BALFOUR HH RASHEED S HOLLINGER FB FISCHL MA VOLBERDING P GROUP TACT
Citation: V. Degruttola et al., SERUM P24 ANTIGEN LEVEL AS AN INTERMEDIATE END-POINT IN CLINICAL-TRIALS OF ZIDOVUDINE IN PEOPLE INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1, The Journal of infectious diseases, 169(4), 1994, pp. 713-721
ZIDOVUDINE RESPONSE RELATIONSHIPS IN EARLY HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
Authors: SALE M SHEINER LB VOLBERDING P BLASCHKE TF
Citation: M. Sale et al., ZIDOVUDINE RESPONSE RELATIONSHIPS IN EARLY HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION, Clinical pharmacology and therapeutics, 54(5), 1993, pp. 556-566
Risultati: 1-11 |